Malignant Mesothelioma

• Muut tekijät: L. Pouliquen, Daniel (Toimittaja), Kopecka, Joanna (Toimittaja)
• Aineistotyyppi: Elektroninen Kirjan osa
• Kieli: englanti
• Julkaistu: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
• Aiheet: Medicine; well-differentiated papillary mesothelioma; WDPM; malignant mesothelioma; DNA sequencing; mutation; mesothelioma; tumor suppressor; targeted therapy; immunotherapy; biomarkers; proteomics; macrophage-capping protein; fatty acid-binding protein; laminin subunit beta-2; selenium-binding protein 1; carcinogenesis; malignant pleural mesothelioma; asbestos exposure; DNA methylation; lymphocyte-to-monocyte ratio; epigenome-wide analysis; survival analysis; metabolomics; radiotherapy; cancers; inflammation; infiltrating immune cells; prognostic biomarker; predictive biomarker; immune therapy; VATS; extrapleural pneumonectomy; pleurectomy decortication; therapy response; survival; FDG; PET-CT; mesothelium; oxidative stress; redox-sensitive factors; asbestos; carbon nanotubes; protein-protein interactions; systems biology; network analysis; drug repurposing; pleural mesothelioma; gene expression; immunogenicity; sarcomatoid; epithelioid; first line; meta-analysis; systematic review; MPM; lurbinectedin; DNA damage response; histotype; Hippo pathway; NF2; BAP1; CDKN2A; PTCH1; SETD2; MTAP; liquid biopsies; circulating tumor DNA; plasma; cancer-specific mutations; genomics; cancer biomarkers; tumor microenvironment; tumor-associated macrophages; dendritic cells; immunohistochemistry; interaction analysis; pleural effusion; n/a
• Linkit: DOAB: download the publication; DOAB: description of the publication

Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many conc...